

# INTRODUCING Pr **pms-DIMETHYL FUMARATE**

A generic equivalent to TECFIDERA®  
at a lower cost



Demonstrated  
bioequivalent to  
TECFIDERA®<sup>1</sup>



Same efficacy  
and safety as  
the brand<sup>1,2</sup>



Patient support program  
available to support patient's  
treatment journey



TECFIDERA®



**pms-DIMETHYL FUMARATE**

For visual comparison only; not actual size.

PRODUCT NAME	FORMAT	DIN	SKU
<b>pms-DIMETHYL FUMARATE 120 mg</b>	Blister pack of 14 capsules	02497026	5760611109
<b>pms-DIMETHYL FUMARATE 120 mg</b>	Blister pack of 56 capsules	02497026	5760602024
<b>pms-DIMETHYL FUMARATE 240 mg</b>	Blister pack of 56 capsules	02497034	5760602025

pms-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules) is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.<sup>1</sup>

The efficacy of dimethyl fumarate delayed-release capsules in patients with primary progressive multiple sclerosis has not been established.<sup>1</sup> pms-DIMETHYL FUMARATE should only be prescribed by clinicians who are experienced in the diagnosis and management of multiple sclerosis.<sup>1</sup>

DIN: drug identification number; SKU: stock-keeping unit  
TECFIDERA® is a registered trademark of Biogen Canada Inc.

1. Pr pms-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules, house standard) Product Monograph. Pharmascience Inc., March 9, 2020.  
2. Pr TECFIDERA® (dimethyl fumarate delayed-release capsules) Product Monograph. Biogen Canada Inc., November 28, 2019.





# The Ally Patient Support Program

## KEY PROGRAM FEATURES:



### FAST FINANCIAL ASSISTANCE

**Support** for access to treatment when starting on pms-DIMETHYL FUMARATE for eligible patients. Electronic coverage via the new online portal is efficient and speeds up the payment process.



### REIMBURSEMENT SUPPORT FOR PATIENTS NEW TO PMS-DIMETHYL FUMARATE

The **Ally Program** helps patients navigate coverage with their payer.



### ONGOING SUPPORT

Over-the-phone assistance for general inquiries

## A SIMPLE ENROLMENT PROCESS



BY EMAIL OR FAX

OR



ON THE ALLY CARE ONLINE PORTAL

1

Fill out the enrolment form and have it signed by the patient.

2

Send the form to the PSP via **email or fax**.

Fill out the enrolment form on the **new Ally Care online portal** at [www.pharmascience.com/canada/patient-support-program/](http://www.pharmascience.com/canada/patient-support-program/). Further steps will be fully managed by the patient support program once patient is enrolled.

## QUESTIONS?

WE ARE HERE TO HELP.



CALL US AT 1-833-ALLY100  
(1-833-255-9100)

or



EMAIL THE EDITABLE PDF TO  
[ally@patientassistance.ca](mailto:ally@patientassistance.ca)